Copy
Press Release June 3, 2020
 

Wuhan General Group Strengthens Team with New Appointments

MONTREAL, QC / ACCESSWIRE / June 3, 2020 /  WUHAN GENERAL GROUP, INC. (WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the newly appointed members of the Company.


Mr. Johann McLoughlin hails from the creative hub of Cape Town, South Africa. He joins Wuhan effective immediately as Director of Product Development and Visual Communications and Design. Prior to joining Wuhan, Mr. McLoughlin worked for more than 10 years in custom and design manufacturing of food and cosmetic products. Mr. Mcloughlin will be responsible for the Dr. AnnaRxTM and MedspressoTM brands. ‘’I’m very excited to take on this challenging role at Wuhan. Building out the company brands into global players is my goal.” said Mr. McLoughlin.


Mr. Selah Abrams resides in Los Angeles and has joined Wuhan as Director of Corporate Strategic Partnerships. Mr. Abrams worked for CNN as a Broadcast Production Engineer for 12 years, and prior to that as Director of Media and Technology for CV Sciences, Inc. an early player in the cannabis sector. He is an expert in the field of supply chain management and logistics. In his role, he will lead and oversee Wuhan’s customer partnership teams, responsible for managing strategic accounts and focusing on the development, management and execution of its initiatives to ensure customer success and growth. 


Mr. Luka Marjanovic will be assuming his new role as Director of Human Resources and Communications effective immediately. Wuhan thanks him greatly for his dedication and hard work in his prior role as a product developer. In his new appointment, Mr. Marjanovic is tasked to lead by sustaining core values and to build effective teams, to ensure and promote a strong desire to reach the goals set by management. High quality internal and external communication is crucial for people´s inclination to act as ambassadors for their company
 
 
Finally, Mr. Rameez Adair of Johannesburg, South Africa has joined the team as Director of Social Media. In his role, Mr. Adair will be responsible for planning, implementing, managing and monitoring Wuhan’s social media strategy in order to increase the Dr. AnnaRxTM and MedspressoTM brand awareness, improve marketing efforts and increase sales.
 

Wuhan CEO Jeff Robinson stated: ‘‘We are on the verge of some very considerable growth and managing it will be critical. Bringing aboard great talent is key for us at this juncture as it provides us all with a greater depth of expertise from which to draw upon and the tools we need to execute and succeed. I’m beyond ecstatic to see our Wuhan planned journey unfold for our shareholders.’’
 
 

About Wuhan General Group, Inc.
 
Wuhan General Group, Inc. through its wholly-owned subsidiary  MJ  MedTech is a  cosmetics and food for special medical purposes  (FSMP)  company with leading alternative plant-based cannabinoids and psilocybin medical research,  formulation and delivery system divisions. Cannabinoids and mushroom-based formulations are under the Dr. AnnaRxTM and MedspressoTM brands. In addition, its established division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients diagnosed with mental health disorders, Alzheimer’s, Parkinson’s, major depressive disorder, drug and alcohol addiction, cardiovascular diseases and PTSD. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
 
 
For further information:
 
Publicly traded company (OTC Pink: WUHN)
Website: www.wuhn.org
E-mail: info@wuhn.org



Forward-Looking Statements

Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.


 
Twitter Twitter
LinkedIn LinkedIn
Facebook Facebook
 
 

                     Wuhan General Group, Inc.  |  6500 Transcanada Hwy 400   |  Quebec, Canada H9R0A5

 

Copyright © 2020 Wuhan General Group or its affiliates. All rights reserved. Medspresso, the logo, and all other related logos are trademarks of Wuhan General Group Inc or its affiliates.

You've received this email because  you opted in via our website or have shown an interest in the past. If you wish to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

 

Email Marketing Powered by Mailchimp